Adnan Deronic (Former)

1 – 10 of 11

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/med-ade?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
next »

2023
Mark The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
Nelson, Michelle H. ; Fritzell, Sara ^LU ; Miller, Robert ; Werchau, Doreen ; Van Citters, Danielle ; Nilsson, Anneli ; Misher, Lynda ; Ljung, Lill ; Bader, Robert and Deronic, Adnan ^LU , et al. (2023) In Molecular Cancer Therapeutics 22(1). p.89-101
- Contribution to journal › Article
2022
Mark Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Hägerbrand, Karin ^LU ; Varas, Laura ^LU ; Deronic, Adnan ^LU ; Nyesiga, Barnabas ; Sundstedt, Anette ^LU ; Ljung, Lill ; Sakellariou, Christina ^LU ; Werchau, Doreen ; Thagesson, Mia and Gomez Jimenez, David ^LU , et al. (2022) In Journal for ImmunoTherapy of Cancer 10(11).
- Contribution to journal › Article
2021
Mark The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
Deronic, Adnan ^LU ; Nilsson, Anneli ; Thagesson, Mia ; Werchau, Doreen ; Enell Smith, Karin ^LU and Ellmark, Peter ^LU (2021) In Cancer Immunology, Immunotherapy 70(12). p.3629-3642
- Contribution to journal › Article
Mark Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Enell Smith, Karin ^LU ; Deronic, Adnan ^LU ; Hägerbrand, Karin ^LU ; Norlén, Per ^LU and Ellmark, Peter ^LU (2021) In Expert Opinion on Biological Therapy 21(12). p.1635-1646
- Contribution to journal › Scientific review
2018
Mark The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis
Fransén Pettersson, Nina ^LU ; Deronic, Adnan ^LU ; Nilsson, Julia ^LU ; Hannibal, Tine ^LU ; Hansen, Lisbeth ^LU ; Schmidt-Christensen, Anja ^LU ; Ivars, Fredrik ^LU and Holmberg, Dan ^LU (2018) In PLoS ONE 13(9).
- Contribution to journal › Article
2016
Mark The anti-tumor effect of the quinoline-3-carboxamide tasquinimod : Blockade of recruitment of CD11b⁺ Ly6C^hi cells to tumor tissue reduces tumor growth
Deronic, Adnan ^LU ; Leanderson, Tomas ^LU and Ivars, Fredrik ^LU (2016) In BMC Cancer 16(1).
- Contribution to journal › Article
2015
Mark Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson, Anders ; Nakhlé, Jessica ; Sundstedt, Anette ; Plas, Pascale ; Bauchet, Anne-Laure ; Pierron, Valérie ; Bruetschy, Luce ; Deronic, Adnan ^LU ; Törngren, Marie and Liberg, David , et al. (2015) In Journal for ImmunoTherapy of Cancer 3.
- Contribution to journal › Article
Mark A1M/α1-microglobulin is proteolytically activated by myeloperoxidase, binds its heme group and inhibits low density lipoprotein oxidation.
Cederlund, Martin ^LU ; Deronic, Adnan ^LU ; Pallon, Jan ^LU ; Sørensen, Ole E ^LU and Åkerström, Bo ^LU (2015) In Frontiers in Physiology 6.
- Contribution to journal › Article
Mark Effect of quinoline-3-carboxamides on myeloid cells in inflammation and cancer
Deronic, Adnan ^LU (2015) In Lund University Faculty of Medicine Doctoral Dissertation Series 2015:90.
- Thesis › Doctoral thesis (compilation)
2014
Mark The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects.
Deronic, Adnan ^LU ; Helmersson, Sofia ^LU ; Leanderson, Tomas ^LU and Ivars, Fredrik ^LU (2014) In International Immunopharmacology 18(2). p.290-297
- Contribution to journal › Article

« previous
1
2
next »